Edward Holland, MD
Ophthalmology · Edgewood, KYNPI 1720021199
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $465,976 of the $677,841 with a category attached, or 68.7%. 27 manufacturers reported payments, led by Kala Pharmaceuticals, Inc. at 29.4% of the total. Among ophthalmology clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 316 payments — averaging $2145.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kala Pharmaceuticals, Inc.$199K
- Alcon$159K
- Johnson & Johnson Surgical Vision, Inc.$124K
- Glaukos Corporation$85K
- Alcon Research LLC$30K
- Novartis$29K
- plus $53K from 21 others
Across 75 payments — averaging $10,066 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$392K
- Sight Sciences, Inc.$153K
- Novartis$83K
- Bausch Health US, LLC$37K
- Aerie Pharmaceuticals, Inc.$35K
- Oyster Point Pharma, Inc.$30K
- plus $26K from 3 others
What the payments were for
- Consulting fees$465,97669%
- Speaking & faculty fees$58,6209%
- Grants$12,0002%
- Travel & lodging$9230%
- Food & beverage$6,9301%
- Other$133,39220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kala Pharmaceuticals, Inc. | 71 | $199,055 |
| Alcon | 37 | $159,163 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $123,553 |
| Glaukos Corporation | 19 | $84,805 |
| Alcon Research LLC | 25 | $29,581 |
| Novartis | 44 | $28,572 |
| Sight Sciences, Inc. | 23 | $12,689 |
| Carl Zeiss Meditec, Inc. | 10 | $9,889 |
| Dompe US, Inc. | 7 | $6,555 |
| Ocular Therapeutix, Inc. | 3 | $5,269 |
| Aerie Pharmaceuticals, Inc. | 5 | $5,194 |
| Merck Kgaa | 3 | $4,270 |
| Oyster Point Pharma, Inc. | 7 | $2,524 |
| Shire North American Group Inc | 5 | $2,082 |
| Eyevance Pharmaceuticals LLC | 3 | $1,034 |
| Eyepoint US, Inc. | 3 | $1,017 |
| AbbVie(2 entities) | 10 | $864 |
| Tearlab Corp | 2 | $547 |
| Harrow Eye, LLC | 5 | $407 |
| Tarsus Pharmaceuticals, Inc. | 4 | $247 |
| Bausch & Lomb Americas Inc. | 7 | $131 |
| Biotissue Holdings Inc. | 4 | $128 |
| Sun Pharmaceutical Industries Inc. | 5 | $79 |
| Regeneron Healthcare Solutions, Inc. | 2 | $59 |
| Alimera Sciences, Inc. | 3 | $58 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $51 |
| Coherus Oncology, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYSUVIS$145,028
- iStent Trabecular Micro-Bypass Stent System$50,162
- iStent inject Trabecular Micro-Bypass Stent System$45,162
- MEIBOMIAN GLAND EVALUATOR$45,000
- XIIDRA$22,670
- iStent inject W$20,148
- iStent$20,000
- ILUX$14,000
- CALLISTO eye$7,500
- TearCare SmartLid$6,938
- TEARCARE(TM) (2.2) SYSTEM KIT$6,938
- Oxervate$6,500
- Centurion$5,775
- ARGOS$5,600
- IOLMaster$5,500
- DEXTENZA$5,200
- DUREZOL$5,040
- DAILIES$4,900
- TearCare$4,391
- CIRRUS HD-OCT$4,000
How this compares
$677,841 in reported general payments places this provider in the 95th percentile of 216 ophthalmology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 28 | $1,122,183 |
| RestasisCyclosporine | 174 | $143,269 |
| Loteprednol Etabonate | 208 | $35,613 |
| Difluprednate | 261 | $34,122 |
| XiidraLifitegrast | 42 | $31,535 |
| Prednisolone Acetate | 741 | $27,466 |
| Cyclosporine | 68 | $23,145 |
| MoxifloxacinMoxifloxacin Hcl | 491 | $17,510 |
| Tacrolimus | 151 | $17,306 |
| IlevroNepafenac | 43 | $15,680 |
| Mycophenolate Mofetil | 226 | $14,938 |
| InveltysLoteprednol Etabonate | 25 | $12,863 |
| TyrvayaVarenicline Tartrate | 13 | $9,799 |
| Lotemax SmLoteprednol Etabonate | 25 | $9,503 |
| ValacyclovirValacyclovir Hcl | 172 | $9,446 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $6,555 | $1,122,18328 claims |
| AbbVieRestasis, Combigan | $864 | $147,142186 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax Sm, Prolensa | $51 | $51,254251 claims |
| Bausch & Lomb Americas Inc.Xiidra | $131 | $31,53542 claims |
| NovartisIlevro | $28,572 | $15,68043 claims |
| Kala Pharmaceuticals, Inc.Inveltys | $199,055 | $12,86325 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $2,524 | $9,79913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 216 ophthalmology providers in Kentucky.
Other ophthalmology in Edgewood
- Kian MadjediEdgewood$3K
- Gary WortzLexington$159K
- Jeremy ClarkLouisville$131K
- Bruce KofflerLexington$49K
- Guruprasad PattarLouisville$36K
- Jeffery TaylorPaducah$18K
- Asim PirachaLexington$17K
- Gary FoulksLouisville$16K
- Christopher ComptonLouisville$13K
- Ryan SmithLexington$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.